Last reviewed · How we verify
Methral (fluperolone)
Methral (generic name: fluperolone) is a drug. It is currently in unknown development.
Methral works by interacting with a specific biological target to produce a therapeutic effect.
Methral (fluperolone) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. Methral is used to treat unknown indications, and its key safety considerations are also unknown. Further research is needed to understand its pharmacological properties and clinical applications.
At a glance
| Generic name | fluperolone |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Imagine your body's cells have locks on them, and Methral is a key that fits into those locks. When it binds to the lock, it triggers a response that helps to treat a particular condition. This is a simplified explanation of how Methral works at a molecular level.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methral CI brief — competitive landscape report
- Methral updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Methral
What is Methral?
How does Methral work?
What is the generic name of Methral?
What development phase is Methral in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing